Edition:
United States

Profile: Onconova Therapeutics Inc (ONTX.PH)

ONTX.PH on Philadelphia Stock Exchange

4.07USD
11 Apr 2019
Change (% chg)

-- (--)
Prev Close
$4.07
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
426
52-wk High
$10.60
52-wk Low
$1.77

Onconova Therapeutics, Inc., incorporated on December 22, 1998, is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers.

Rigosertib

Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a Ras mimetic. The Company has completed enrollment in the Phase II portion of an open label Phase I/II clinical trial testing rigosertib oral in combination with the approved dose of injectable azacitidine for patients with higher-risk MDS and acute myelogenous leukemia (AML).

Briciclib

The Company's product candidate, Briciclib, is a small molecule targeting an important intracellular regulatory protein, cyclin D1, which is often found at elevated levels in cancer cells. Cyclin D1 expression is regulated through a process termed cap-dependent translation, which requires the function of eukaryotic initiation factor 4E (eIF4E) protein. The Company is conducting a Phase I multisite dose-escalation trial of briciclib in patients with advanced solid tumors.

Recilisib

The Company's product candidate, Recilisib, is being developed for acute radiation syndromes. The Company has completed over four Phase I trials to evaluate the safety and pharmacokinetics of recilisib in healthy human adult subjects using both subcutaneous and oral formulations.

The Company competes with Eisai Inc., Celgene Corporation, Cell Therapeutics, Inc., Cyclacel Pharmaceuticals, Inc., Astex/Otsuka, Array BioPharma Inc, Acceleron Pharma, Soligenix, Inc., Cellerant Therapeutics, Inc. and Cleveland BioLabs, Inc.

Company Address

Onconova Therapeutics Inc

375 Pheasant Run
NEWTOWN   PA   18940
P: +1267.7593681
F: +1302.6365454

Company Web Links